Short-term Effectiveness of Gabapentin Versus Placebo in Acute Lumbosacral Radiculalgia by Herniation Disc (GRADE)

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study consists in evaluating the analgesic efficacy of Gabapentin versus Placebo in the short term (72h) acute lumbosacral radiculalgia due to disc herniation.

In addition to the usual analgesic treatment, the patient will receive gabapentin or placebo.

During the three days of treatment, an evaluation of the pain and the tolerance will be performed within the two groups: experimental and control.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lille Catholic University
• Treatments: Gabapentin

Criteria

Inclusion Criteria:

• Age ≥ 18 years,

• Radiculalgia or lumboradiculalgia less than 3 months (pain of a lower limb systematized to a radicular territory, possibly associated with lumbar pain),

• Inpatient management for a minimum of 72 hours after inclusion,

• Initial radiculalgia VAS ≥ 4 (moderate to severe pain),

• Concordant disc herniation between clinical symptomatology and imaging (CT or MRI) less than 3 months,

• Written consent signed by the patient,

• Affiliation to a social security system

• For women of childbearing age, use of effective contraception

Exclusion Criteria:

• Motor neurological deficit (≤ 3/5) or cauda equina syndrome (emergency surgical indications),

• History of lumbar surgery,

• History of pre-existing neuropathic pain in the lower limb affected by radiculalgia,

• Lumbar infiltration performed within 72 hours prior to inclusion or unable to be performed after 72 hours,

• Patient already on Gabapentin or Pregabalin, or having taken these treatments in the 7 days prior to inclusion

• Contraindication to Gabapentin (Hypersensitivity to the active substance or to any of the excipients: corn starch, talc, yellow iron oxide, titanium dioxide, sodium lauryl sulfate, gelatin, shellac, propylene glycol, black iron oxide and potassium hydroxide)

• Creatinine clearance < 30ml/min,

• Hemodialysis patient,

• Body weight < 50kgs,

• Transplant patient

• Patient under guardianship or curatorship

• Pregnant or breastfeeding woman